OpGen (LTS:0A8L) Inventories, Finished Goods : $0.00 Mil (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is OpGen Inventories, Finished Goods?

OpGen's annual finished goods declined from Dec. 2021 ($3.74 Mil) to Dec. 2022 ($0.00 Mil) but then stayed the same from Dec. 2022 ($0.00 Mil) to Dec. 2023 ($0.00 Mil).

OpGen Inventories, Finished Goods Historical Data

The historical data trend for OpGen's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OpGen Inventories, Finished Goods Chart

OpGen Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Inventories, Finished Goods

Get a 7-Day Free Trial

0.12

2.31

3.74

OpGen Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Inventories, Finished Goods	Get a 7-Day Free Trial															-	-	-	-	-

OpGen Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

OpGen Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » OpGen Inc (LTS:0A8L) » Definitions » Inventories, Finished Goods

Comparable Companies

Traded in Other Exchanges

OPGN:USA

Address

9717 Key West Avenue, Suite 100, Rockville, MD, USA, 20850

Website

https://www.opgen.com

OpGen Inc is a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease. It is developing molecular information products and services for healthcare settings, helping to guide clinicians with rapid and actionable information about life-threatening infections, improve patient outcomes, and decrease the spread of infections caused by MDROs. Its proprietary DNA tests and informatics address the rising threat of antibiotic resistance by helping physicians and other healthcare providers optimize care decisions for patients with acute infections. The company's product candidates and services combine its Acuitas molecular diagnostics and Acuitas Lighthouse informatics platform for use with its curated MDRO knowledge base.

OpGen Headlines

No Headlines